Initial treatment options for relapsed/refractory multiple myeloma patients
11 Dec 2021
Initial treatment options for relapsed/refractory multiple myeloma patients
ZUMA-5 update: Axicabtagene ciloleucel continues to show strong effect in R/R iNHL
Lisocabtagene maraleucel demonstrates improvement over standard of care in 2L LBCL
Latest in advanced endometrial cancer
Oncology nursing in the global south during COVID-19
OncoAlert and ecancer weekly round up for November 29th - December 5th, 2021
Post-HSCT management of ALL - Adult ALL perspective
Quality of life and patient perspectives in renal cell carcinoma
Latest in diagnostics in EGFR mutated NSCLC
The Lancet Commission on women and cancer
Safety profile of BiTE therapy
Treating late relapse of paediatric ALL